Squarepoint Ops LLC lifted its stake in shares of Upstream Bio, Inc. (NASDAQ:UPB - Free Report) by 551.9% during the second quarter, according to its most recent filing with the Securities & Exchange Commission. The firm owned 290,904 shares of the company's stock after acquiring an additional 246,278 shares during the period. Squarepoint Ops LLC owned 0.53% of Upstream Bio worth $2,013,000 at the end of the most recent reporting period.
Several other institutional investors and hedge funds have also bought and sold shares of UPB. Walleye Capital LLC bought a new position in shares of Upstream Bio during the 2nd quarter worth about $3,450,000. Arrowstreet Capital Limited Partnership acquired a new stake in shares of Upstream Bio in the 1st quarter valued at about $1,666,000. BlackRock Inc. bought a new stake in Upstream Bio in the 2nd quarter valued at about $25,973,000. Deutsche Bank AG bought a new stake in Upstream Bio in the 2nd quarter valued at about $1,671,000. Finally, Parkman Healthcare Partners LLC acquired a new position in Upstream Bio during the 2nd quarter worth approximately $6,472,000.
Upstream Bio Stock Performance
UPB stock opened at $5.81 on Tuesday. The company has a market capitalization of $318.21 million, a P/E ratio of -2.00 and a beta of 1.28. Upstream Bio, Inc. has a 52-week low of $5.65 and a 52-week high of $33.68. The business has a 50-day simple moving average of $6.78 and a two-hundred day simple moving average of $7.80.
Upstream Bio (NASDAQ:UPB - Get Free Report) last issued its quarterly earnings data on Tuesday, August 11th. The company reported ($0.73) EPS for the quarter, topping analysts' consensus estimates of ($0.74) by $0.01. Upstream Bio had a negative return on equity of 48.40% and a negative net margin of 4,955.67%.The firm had revenue of $0.77 million during the quarter, compared to analyst estimates of $0.56 million. As a group, sell-side analysts forecast that Upstream Bio, Inc. will post -2.84 earnings per share for the current fiscal year.
Wall Street Analyst Weigh In
UPB has been the topic of several recent research reports. Wall Street Zen lowered Upstream Bio from a "sell" rating to a "strong sell" rating in a report on Saturday, August 15th. HC Wainwright restated a "buy" rating and set a $36.00 price objective on shares of Upstream Bio in a report on Wednesday, September 2nd. Weiss Ratings raised Upstream Bio from a "sell (e+)" rating to a "sell (d-)" rating in a research report on Monday, August 17th. Truist Financial cut their target price on Upstream Bio to $25.00 and set a "buy" rating on the stock in a report on Tuesday, August 11th. Finally, JPMorgan Chase & Co. lifted their price target on shares of Upstream Bio from $8.00 to $9.00 and gave the company a "neutral" rating in a research report on Friday, August 14th. Four investment analysts have rated the stock with a Buy rating, two have assigned a Hold rating and one has assigned a Sell rating to the company's stock. Based on data from MarketBeat.com, Upstream Bio has an average rating of "Hold" and a consensus price target of $29.67.
Check Out Our Latest Stock Analysis on Upstream Bio
Upstream Bio Company Profile
(
Free Report)
Upstream Bio, Inc is a clinical-stage biopharmaceutical company focused on developing treatments for inflammatory and immune-mediated diseases. The company's research is centered on targeting biological pathways involved in chronic inflammation, with the goal of addressing conditions that may not be adequately controlled by existing therapies.
Upstream Bio's lead product candidate is verekitug, a monoclonal antibody designed to block thymic stromal lymphopoietin (TSLP), an epithelial-cell-derived cytokine that plays a role in initiating and sustaining allergic and inflammatory responses.
See Also
Want to see what other hedge funds are holding UPB? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Upstream Bio, Inc. (NASDAQ:UPB - Free Report).
This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.
Before you consider Upstream Bio, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Upstream Bio wasn't on the list.
While Upstream Bio currently has a Hold rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Tesla, Nvidia, and Google helped shape the last era of market growth, but the next wave could come from a new group of companies. Inside this report, you’ll find 7 stocks that could play a major role in the next tech-driven market boom.
Get This Free Report
Continue following MarketBeat
Add MarketBeat as your preferred source on Google to see our latest stories in your feed.
Like this article? Share it with a colleague.
Link copied to clipboard.
